AstraZeneca net climbs 31%, helped by strong sales of Crestor

Article Abstract:

AstraZeneca PLC of the United Kingdom posted a second quarter soaring net profit increase of 31 percent to $1.6 billion, up from $1.22 billion last year. Revenues were buoyed by sales of top pharmaceuticals, particularly breast cancer drug Arimidex and Cholesterol drug Crestor.

Pharmaceutical preparations, Pharmaceutical industry, Company sales and earnings, AstraZeneca PLC, Company earnings/profit, AZN, Company overview

---

Autonomy is facing an uncertain forecast

Article Abstract:

Autonomy Corp. expects to reach analysts' earnings forecasts for the 2001 second-quarter. However, the company is continuing to see contract deferrals which may affect its results after the second-quarter.

Autonomy Corporation PLC

---

Biodata cuts forecasts

Article Abstract:

Biodata Information Technology AG is forecasting a major decline in its sales and earnings for the 2001 third-quarter and full-year. The company blamed the forecast on the global economic slowdown.

Information technology, Biodata Information Technology

Similar abstracts:

• Abstracts: AstraZeneca gets close to end of auction of unit. Novartis AG emerges as suitor for Monsanto. Abbott Will Acquire BASF's Knoll Unit
• Abstracts: Beijing: bright lights, big city. Maintaining a sense of history. Work smarter, not harder and learn to say no
• Abstracts: More declines in chip sales. Intel offers chip set earlier
• Abstracts: Analysts feel the heat. Asia ties prosperity to IT
• Abstracts: Ericsson revamps management amid intensified competition. Telia seeks to buy SBC's 41.6% stake in TeleDanmark

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.